Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | AURKA | O14965 | 2/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4595357 | 0.88 | SMN1; SMN2 (0.53) | KMT2AMEN1SMN1; SMN2AURKAAURKB | |
| SCHEMBL5027766 | 0.87 | SMN1; SMN2 (0.46) | KMT2AMEN1SMN1; SMN2L3MBTL1POLB | |
| SCHEMBL5025349 | 0.85 | L3MBTL1 (0.55) | KMT2AMEN1L3MBTL1MAPTLMNA | |
| SCHEMBL5025176 | 0.84 | ALDH1A1 (0.48) | KMT2AMEN1SMN1; SMN2MAPTLMNA | |
| SCHEMBL5041435 | 0.83 | AURKA (0.53) | KMT2AMEN1SMN1; SMN2AURKAAURKB | |
| SCHEMBL5025301 | 0.81 | TSHR (0.53) | KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL12523205 | 0.80 | AURKA (0.51) | KMT2AMEN1SMN1; SMN2AURKAAURKB | |
| SCHEMBL5045422 | 0.80 | KMT2A (0.46) | KMT2AMEN1SMN1; SMN2PKML3MBTL1 | |
| SCHEMBL5027736 | 0.78 | AURKA (0.49) | KMT2AMEN1SMN1; SMN2AURKAAURKB | |
| SCHEMBL6469861 | 0.77 | MEN1 (0.57) | KMT2AMEN1SMN1; SMN2PKML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238576-A1 | Triazine Derivatives and their Therapeutical Applications | CALIFORNIA CAPITAL EQUITY, LLC (CA) | 2012-09-20 | — | — | US | disclosed |
| US-8124759-B2 | Inhibitors of protein kinases | ABBOTT LABORATORIES (US) | 2012-02-28 | — | — | US | disclosed |
| EP-1899345-B1 | PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-2150553-B1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | ABBOTT LAB (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-2297151-A1 | INHIBITORS OF PROTEIN KINASES | Abbott Laboratories (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010144338-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
| EP-2150553-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | Abbott Laboratories (US) | 2010-02-10 | — | — | EP | disclosed |
| WO-2009136966-A1 | INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090131425-A1 | INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090023743-A1 | INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (IL) | 2009-01-22 | — | — | US | disclosed |
| CN-1753889-A | Quinazoline compounds | ASTRAZENECA AB (SE) | 2006-03-29 | — | — | CN | disclosed |
| US-20060058523-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-20060046987-A1 | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2006-03-02 | — | — | US | disclosed |
| EP-1575946-A1 | QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| US-6919338-B2 | Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase | ASTRAZENECA AB (SE) | 2005-07-19 | — | — | US | disclosed |
| WO-2004058752-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
| CN-1496364-A | Substituted quinazoline derivatives and their use as inhibitors | — | 2004-05-12 | — | — | CN | disclosed |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | US | disclosed |
| EP-1299381-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | AstraZeneca AB (SE) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002000649-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131425-A1 | INHIBITORS OF PROTEIN KINASES | AURKC, AURKB, PLK1 | KMT2A 1632/4885MEN1 950/4885SMN1; SMN2 2414/4885 |
| US-20060058523-A1 | Quinazoline compounds | NDUFS5, ABL1, NDUFS7 | KMT2A 2083/4885MEN1 1897/4885SMN1; SMN2 1989/4885 |
| US-20090023743-A1 | INHIBITORS OF PROTEIN KINASES | AURKC, AURKB, PLK1 | KMT2A 1632/4885MEN1 950/4885SMN1; SMN2 2414/4885 |
| US-20120238576-A1 | Triazine Derivatives and their Therapeutical Applications | SLC10A1, GLS, SLC10A2 | KMT2A 2859/4885MEN1 3798/4885SMN1; SMN2 1360/4885 |
| US-20060046987-A1 | Substituted quinazoline derivatives and their use as inhibitors | AURKA, AURKB, AURKC | KMT2A 909/4885MEN1 1888/4885SMN1; SMN2 3417/4885 |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | AURKA, AURKC, AURKB | KMT2A 790/4885MEN1 2422/4885SMN1; SMN2 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.